The Federal Trade Commission has filed a lawsuit against the World Professional Association for Transgender Health, joined by the states of Alaska, Iowa, Nebraska, and Texas. The claim is that WPATH made deceptive claims about gender-affirming care for minors and that its members profited from those claims. This is not a consumer-protection action. It is an attempt to use federal law to dismantle the evidence base for trans healthcare.
What is WPATH, and why does it matter?
WPATH has been setting the clinical standards for gender-affirming care for more than fifty years. Its Standards of Care are the framework most gender clinicians around the world work within. They are built on peer-reviewed research, expert consensus, and decades of clinical experience. When a doctor in London, Sydney, or São Paulo wants to understand what good gender-affirming care looks like, they turn to WPATH. The organisation is not a fringe lobby group. It is the body that writes the guidelines, and those guidelines are endorsed by the World Health Organisation, the American Medical Association, the Endocrine Society, and a long list of other major medical organisations.
So when the FTC chair, Andrew Ferguson, says that parents deserve to be protected from medical organisations that prioritise profit over children's safety, a federal regulator is suing the body that writes the evidence-based guidelines because the current administration does not like what the evidence says.
This is part of a pattern
The FTC has also launched investigations into the American Academy of Pediatrics and the Endocrine Society over their guidelines on gender-affirming care. Both of those organisations have sued to protect themselves. WPATH itself sued to block the FTC investigation earlier, arguing that the agency was violating its First Amendment rights, and a federal judge ruled in WPATH's favour in May, temporarily blocking the investigation. The fact that a lawsuit has now been filed anyway tells you something about how much this administration respects that ruling.
WPATH has said plainly that it expects the same outcome when it challenges the lawsuit. The organisation's position is that the FTC is acting out of retaliation as part of a broader campaign to undermine gender-affirming care by attacking the independence of professional medical organisations. I think that is exactly right.
What does "deceptive claims" actually mean here?
The FTC's language is worth examining. Consumer-protection law exists to stop companies from lying to customers to make money, think false advertising, dodgy supplements, pyramid schemes. Applying that framework to a medical organisation publishing clinical guidelines is a significant stretch, and it is worth asking why that stretch is being made.
WPATH is not selling a product. It publishes evidence-based guidance for clinicians. Its guidelines explicitly call for care tailored to the individual patient rather than any fixed protocol. If the FTC's real concern were the welfare of trans young people, it would be engaging with the clinical evidence. It is not doing that. It is using the courts to intimidate the organisations that produce that evidence.
The Endocrine Society. The American Academy of Pediatrics, which reaffirmed its support for evidence-based gender-affirming care in 2025 in direct response to federal pressure. And now WPATH. The administration is not picking fights with fringe voices. It is going after the mainstream of medical science because the mainstream of medical science does not support what the administration is trying to do.
What happens to real people when you attack the guidelines?
People tell me, again and again, that the hardest part of being trans or of raising a trans child is not the identity itself. It is the uncertainty: not knowing whether care will be available, not knowing whether the doctor you finally managed to see will still be able to help you next month, not knowing whether the political weather will change before your child gets through a waiting list that already runs to years.
This lawsuit deepens that uncertainty. It signals to every clinician in the United States that providing gender-affirming care could expose them to federal scrutiny. It signals to every medical organisation that publishing guidelines based on evidence is now a legal risk. The effect, whether or not the lawsuit ultimately succeeds, is a chilling one. Doctors become more cautious. Young people wait longer. Families are left without support.
That is the actual cost of what the FTC is doing here. Not consumer protection. Not safety. Harm, imposed through the courts on some of the most vulnerable young people in America.
The medical consensus is not going away
WPATH has been clear that it will fight this. The federal court has already sided with it once. The evidence base for gender-affirming care is not something a lawsuit can erase: it has been built over decades, by researchers and clinicians working across dozens of countries, replicated and peer-reviewed. Suing WPATH does not make the evidence disappear. It just makes it harder for doctors and families to access the guidance they need.
I hope WPATH wins, and wins decisively. And I hope every medical organisation watching this understands that standing firm matters, not only for the integrity of their own guidelines, but for every trans young person waiting to see a doctor who is still willing to help them.
If there is a news story you would like me to cover then just let Sammy know.
Dr Helen Webberley is a Gender Specialist, Medical Educator, and founder of GenderGP. She writes about gender identity, trans healthcare, and the world around them.
